P
ALNY icon

&Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

&Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.07M Buy
3,230
+533
+20% +$181K 0.01% 1262
2025
Q4 		$1.07M Sell
2,697
-46
-2% -$20.4K 0.01% 1180
2025
Q3 		$1.25M Buy
2,743
+1,213
+79% +$494K 0.01% 979
2025
Q2 		$498K Buy
1,530
+702
+85% +$194K ﹤0.01% 1363
2025
Q1 		$223K Buy
+828
New +$213K ﹤0.01% 1571

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

&Partners's ALNY Position: Q1 2026 in Review

&Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 20% in Q1 2026, buying an estimated $181K and bringing the position to 3,230 shares worth $1.07M. The position accounts for 0.01% of the portfolio, ranked #1262.

&Partners first reported a position in ALNY in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.25M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • &Partners held 3,230 shares of Alnylam Pharmaceuticals worth $1.07M as of Q1 2026.
  • &Partners bought 533 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $181K.
  • Alnylam Pharmaceuticals made up 0.01% of &Partners's portfolio in Q1 2026, its #1262 holding.
  • &Partners first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • &Partners's Alnylam Pharmaceuticals position peaked at $1.25M in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.